Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 15;20(3):602–611. doi: 10.1158/1535-7163.MCT-20-0412

Figure 4.

Figure 4.

Continuous therapy with anti-TGF-β monoclonal antibody starting prior to tumor cell injection and continuing for 6 weeks. (A) Maintenance therapy schema. Decrease in both (B) ascites volume and (C) omental weights. (D-F) Consistent pattern of T cell profile with treatment including (D) CD8 T cells, (E) Tregs and (F) CD8:Treg ratio. (G) Overall survival is improved (median survival of 57.5 days vs 70 days) with continuous anti-TGF-β therapy (* p < 0.05, ** p < 0.01, bars represent SEM; dotted line – mean weight of naïve mouse omentum).